Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, two-way crossover study, to evaluate the effect of a single oral dose of BNC210 on CCK-4 induced panic-like symptoms in healthy young male subjects.

Next Previous
Search
Trial Profile

A randomised, double-blind, placebo-controlled, two-way crossover study, to evaluate the effect of a single oral dose of BNC210 on CCK-4 induced panic-like symptoms in healthy young male subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders; Panic symptoms
  • Focus Pharmacodynamics

    • Most Recent Events

    • 15 Nov 2011 Results were reported at the 41st Annual Meeting of the Society for Neuroscience, according to a Bionomics media release.
    • 30 Mar 2011 Primary endpoint 'Symptom-rate' has been met.
    • 30 Mar 2011 Positive preliminary results have been reported in a Bionomics media release; the company anticipates that data from this trial will be presented at a major scientific conference later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top